177Lu-PSMA治疗复发性高级别胶质瘤:剂量学洞察的初步研究
该初步研究评估了177Lu-PSMA治疗复发性高级别胶质瘤的可行性与潜在临床获益。基于68Ga-PSMA-PET阳性筛选患者,每6-8周给予177Lu-PSMA 7.4 GBq/200 mCi。结果显示治疗可行且耐受良好,无3-4级毒性,部分患者影像学稳定,但肿瘤吸收剂量中位每周期仅0.9 Gy,中位无进展生存45天。
要点
- 177Lu-PSMA在复发性高级别胶质瘤中可行且耐受良好,未出现CTCAE 3-4级毒性。
- 肿瘤中位吸收剂量每周期仅0.9 Gy,低于肾脏2.6 Gy和腮腺1.7 Gy。
- 中位无进展生存45天,中位总生存187天,部分患者MRI显示疾病稳定。
核心结论
- 177Lu-PSMA治疗复发性高级别胶质瘤可行且耐受良好,部分患者出现影像学稳定,但可能需要提高肿瘤剂量递送以改善疗效。
研究设计与样本
- 初步研究纳入10例复发性高级别胶质瘤患者,其中WHO 4级胶质母细胞瘤6例、WHO 4级星形细胞瘤1例、WHO 3级星形细胞瘤3例。
- 基于68Ga-PSMA-PET阳性筛选治疗对象,177Lu-PSMA按7.4 GBq/200 mCi每6-8周给药,直至耐受。
主要发现
- 治疗前68Ga-PSMA-PET显示9例患者肿瘤摄取,中位SUVmax为6.4(IQR 4.2-9.0)。
- 6例患者接受治疗,共20个周期,每人1-7周期。
- 肿瘤每周期中位吸收剂量0.9 Gy(IQR 0.8-1.1),肾脏2.6 Gy(IQR 1.9-3.2),腮腺1.7 Gy(IQR 1.5-2.2)。
- 未发生CTCAE 3-4级毒性,最常见患者报告症状为乏力、一过性口干和恶心。
- 自治疗开始中位生存187天(范围87-756),中位无进展生存45天(范围41-335);MRI(RANO 2.0)显示半数患者在全部或部分治疗过程中疾病稳定。
关键数值与推荐
- 177Lu-PSMA给药活度为7.4 GBq/200 mCi,间隔6-8周。
- 肿瘤每周期中位吸收剂量0.9 Gy(IQR 0.8-1.1),肾脏2.6 Gy(IQR 1.9-3.2),腮腺1.7 Gy(IQR 1.5-2.2)。
- 治疗前68Ga-PSMA-PET肿瘤摄取中位SUVmax为6.4(IQR 4.2-9.0)。
临床怎么用
- 对复发性高级别胶质瘤患者,可基于68Ga-PSMA-PET阳性筛选后尝试177Lu-PSMA治疗。
- 治疗期间需通过PET/MRI、SPECT/CT、血液检查、神经学检查和患者报告结局进行安全性及疗效监测。
局限性
- 本研究为初步研究,样本量仅10例,其中仅6例实际接受治疗。
- 原文未报告随机对照或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clin Nucl Med . 2026 Oct 28. doi: 10.1097/RLU.0000000000006692. Online ahead of print. ABSTRACT PURPOSE: Patients with recurrent high-grade glioma have poor prognosis and limited treatment options. This pilot study evaluated the feasibility and potential clinical benefit of 177Lu-PSMA therapy in this patient population. PATIENTS AND METHODS: Eligible patients were selected for treatment based on positive 68Ga-PSMA-PET findings. 177Lu-PSMA (7.4 GBq/200 mCi) was administered at 6-8-week intervals and continued as long as well-tolerated. The safety, tolerability, and efficacy of 177Lu-PSMA were assessed in each treatment cycle using PET/MRI, SPECT/CT, blood tests, neurological tests, and patient-reported outcome measures. RESULTS: Ten patients were enrolled (WHO grade 4 glioblastoma, n=6; WHO grade 4 astrocytoma, n=1; WHO grade 3 astrocytoma, n=3). 68Ga-PSMA-PET before treatment demonstrated tumor uptake in 9 patients (median SUVmax: 6.4, IQR: 4.2-9.0). Six patients received treatment (20 cycles total; range: 1-7 per patient). Median absorbed dose per cycle was 0.9 Gy (IQR: 0.8-1.1) for tumors, 2.6 Gy (IQR: 1.9-3.2) for kidneys, and 1.7 Gy (IQR: 1.5-2.2) for parotid glands. No CTCAE grade 3-4 toxicities occurred. The most common patient-reported symptoms were fatigue, transient xerostomia, and nausea. Median survival from treatment initiation was 187 days (range: 87-756) and the median progression-free survival was 45 days (range: 41-335). MRI (RANO 2.0) demonstrated stable disease in half of the patients during all or part of the treatment course. CONCLUSIONS: 177Lu-PSMA therapy was feasible and well-tolerated. Radiologic stabilization was observed in a subset of patients, but strategies to increase tumor dose delivery may be needed to improve efficacy. PMID: 42949152 | DOI: 10.1097/RLU.0000000000006692
引用
- PubMed · Clin Nucl Med:177Lu-PSMA Therapy in Recurrent High-Grade Glioma: A Pilot Study With Dosimetric Insights
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。